𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Somatomedin-1-binding-protein-3 promising adjunct to insulin in type 2 diabetes

Book ID
120864395
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2002
Weight
133 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Remissions in newly diagnosed Type 1 (in
Remissions in newly diagnosed Type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy
✍ V. A. Koivisto; A. Aro; K. Cantell; M. Haataja; J. Huttunen; S. -L. Karonen; P. πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 492 KB

We studied the effect of interferon as an adjunct to conventional insulin therapy on the early course of Type 1 diabetes in 43 newly diagnosed patients. Compared with conventional therapy, interferon administration slightly delayed the improvement of glucose homeostasis and the rise of high density

Advanced glycosylation end products (AGE
Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with Type 2 diabetes mellitus
✍ Ma. Eugenia Garay-Sevilla; Laura Eugenia Nava; Juan Manuel Malacara; Kazimierz W πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 126 KB πŸ‘ 1 views

Background Advanced glycosylation end product (AGE) formation is a major mechanism for the development of complications in diabetes, and the possible roles of insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) are not clearly established. ## Methods We examined the associati